BNB Plus Corp. (BNBX)
| Market Cap | 898.75K -78.6% |
| Revenue (ttm) | 2.39M -1.3% |
| Net Income | -35.31M |
| EPS | -6.34 |
| Shares Out | 6.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,592 |
| Open | 0.1301 |
| Previous Close | 0.13363 |
| Day's Range | 0.1301 - 0.1500 |
| 52-Week Range | 0.0660 - 7.1500 |
| Beta | 0.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 17, 2026 |
About BNB Plus
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutica... [Read more]
Financial Performance
In fiscal year 2025, BNB Plus's revenue was $2.14 million, an increase of 1.11% compared to the previous year's $2.11 million. Losses were -$69.49 million, 861.7% more than in 2024.
Financial StatementsNews
BNB Plus Quarterly report: Q3 2026
BNB Plus has published its Q3 2026 quarterly earnings report on August 13, 2026.
BNB Plus Registration statement: Registration filing
BNB Plus filed a registration statement on August 5, 2026, providing details about a securities offering with the SEC.
BNB Plus announces transition to internalized digital asset treasury management
BNB Plus announced that, in furtherance of its ongoing strategic review, it has reached a mutual agreement with Cypress Management and its affiliates to conclude their advisory and asset management…
BNB Plus Corp. (BNBX) Announces Transition to Fully Internalized Digital Asset Treasury Management
STONY BROOK, N.Y.--(BUSINESS WIRE)--BNB Plus Corp. (OTCQB: BNBX) ("BNB Plus" or the "Company") today announced that, in furtherance of its ongoing strategic review, it has reached a mutual agreement w...
BNB Plus Corp. announces Nasdaq delisting determination
BNB Plus has received a delisting determination from the Hearing Panel of the Nasdaq Stock Market as a result of the Company’s non-compliance with the minimum $1.00 bid price requirement…
BNB Plus Corp. (BNBX) Announces Nasdaq Delisting Determination and Transition to OTCQB Market; Company to Seek Review by Nasdaq Listing and Hearing Review Council
STONY BROOK, N.Y.--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company") today announced that it has received a delisting determination from the Hearing Panel of the Nasdaq Stoc...
BNB Plus secures commitments for $4.1M in financing, initiates strategic review
BNB Plus secured initial commitments for $4.1M of convertible preferred stock financing, with additional commitments anticipated to bring total proceeds to $5M. Proceeds from the Financing will be use...
BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced it has secured initial commitments for $4.1M of convertible preferred stock financing, with addi...
BNB Plus ‘continues to execute’ on operating initiatives amid strategic review
As previously announced on April 20, 2026, the Company’s Board of Directors authorized a formal review of strategic alternatives to maximize shareholder value. The Company continues to execute on its…
BNB Plus Corp. completes production of $1.2M LineaDNA order
BNB Plus completed production of its largest order in LineaRx history. The $1.2M order, originally announced in January 2026 with shipments completing in early May 2026, was produced at historically…
BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has successfully completed pro...
BNB Plus Corp. announces review of strategic alternatives
BNB Plus’ Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value and also provided an update on its Nasdaq listing status. The strategic alternatives...
BNB Plus Corp. receives non-compliance notice from Nasdaq
On March 20, the Company received written notice from the Listing Qualifications Department of Nasdaq indicating that the Company no longer satisfies the minimum $1.00 bid price requirement for contin...
BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of...
BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent...
BNB Plus Corp. reports BNB token holdings valued at $10.7M as of February 23
BNB Plus Corp. (BNBX) provided an update on its BNB (BNB-USD) token holdings and digital asset portfolio. The company maintains significant holdings of BNB tokens and OBNB trust units as…
BNB Plus Corp. receives two new orders for LineaDNA
BNB Plus Corp. (BNBX) announced that its biopharmaceutical subsidiary, LineaRx, has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment ...
BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for Lin...
BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Commit...
BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will pres...
BNB Plus Corp. receives $1.2M order for LineaDNA
BNB Plus Corp. (BNBX) announced that it has received a $1.2M order for LineaDNA, representing the largest LineaDNA order in company history. The order is an acceleration of an existing…
BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Comp...
BNB Plus Corp. ships largest single LineaDNA order
BNB Plus Corp. (BNBX) announced that it has manufactured and shipped the largest single LineaDNA order in company history, valued at over $390,000. The approximately five-gram shipment, manufactured b...
BNB Plus Corp. (BNBX) Announces Largest Ever Shipment of LineaDNATM
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has successfully manufactured and shipped the largest single LineaDNA order in Company histo...
BNB Plus says LineaRx subsidiary expected to approach profitability in Q1 2026
BNB Plus announced that following a strategic restructuring and realignment of resources implemented earlier this year, its LineaRx subsidiary has significantly reduced its costs. Based on its reduced...